Porocarcinomas harbor recurrent HRAS-activating mutations and tumor suppressor inactivating mutations.
暂无分享，去创建一个
S. Tomlins | J. Siddiqui | A. Cani | D. Hovelson | K. Omata | M. Haller | Rajiv M. Patel | D. Fullen | P. Harms | A. Andea | Min Wang | Michael L Wang | David P. Arps